The Vitalist Bay gathering signals longevity's pivot from niche biohacking to investor darling, yet the STAT coverage underplays how this mirrors prior wellness cycles where hype outpaces evidence. While the event showcased at-home tests and cryopreservation talks, it glosses over the absence of large-scale RCTs validating biological age reversal claims; most cited interventions rely on observational data from cohorts under 500 participants, often funded by the same startups pitching solutions. This echoes the 2010s nootropics boom, where companies like Bulletproof monetized unproven stacks before peer-reviewed scrutiny revealed minimal effects in controlled trials. Broader patterns show venture capital flooding 'longevity biotech'—Altos Labs raised $3B despite early-stage mouse data—prioritizing patents over human outcomes, with conflicts rife as founders double as conference organizers. Missed in the original: demographic skew toward affluent attendees, sidelining equity issues in access to therapies that remain experimental. Synthesizing with a 2023 Lancet Healthy Longevity review (observational, n=1.2M, industry ties noted) and a JAMA analysis of senolytics (small RCT, n=60, no long-term mortality benefit), the trend risks commodifying aging without addressing root social determinants.